Should biologics for psoriasis be interrupted in the era of COVID-19? - 14/04/20
Funding sources: None. |
|
Disclosure: Dr Lebwohl is an employee of Mount Sinai; receives research funds from AbbVie, Amgen, Eli Lilly, Janssen Research and Development, LLC, Novartis, Ortho Dermatologics, Sanofi-Regeneron, and UCB, Inc; and has been the principal investigator for numerous clinical trials but has no personal financial gain. Dr Murrell is an employee of St George Hospital; has been an investigator/advisor for Novartis, Sun Pharma, Janssen, and AbbVie; and is the director of a clinical trial center for dermatologic diseases. Dr Rivera-Oyola has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Accepted for publication March 11, 2020. |
|
Reprints not available from the authors. |
Vol 82 - N° 5
P. 1217-1218 - mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.